BPL-003 for depression: a promising trial, not an approved treatment

Saved in this browser. Sign in to sync across devices.

participants included in analyses: 193
adjusted primary-outcome difference: 5.3 points

What was tested and what improved?

The JAMA phase 2b trial compared single supervised doses of intranasal mebufotenin benzoate (BPL-003) with a low-dose comparator, alongside psychological support. Eligible ages were 18–75; participants had not responded to two to five antidepressant trials.

Day-29 response rates were 35% (8 mg), 34% (12 mg) and 12% (0.3 mg comparator). Remission rates were 26%, 18% and 8%. The primary 12-mg comparison favored active treatment (95% CI for the adjusted difference: 1.8–8.9 points). Treatment-emergent adverse events occurred in 76%, 85% and 73%, respectively; most were mild or moderate.

Source context: Feifel et al. — JAMA, October 26, 2026

What the numbers do not settle

Response and remission are study definitions, not a guarantee of lasting recovery. A short follow-up cannot establish years of benefit. A noticeable psychedelic experience can make masking difficult, and a low-dose comparator is not a fully inactive placebo.

These findings should not be generalized to children, pregnancy, bipolar depression or psychosis. Nor do they establish that the nasal preparation is interchangeable with other formulations or informal products. The doses above describe research groups, not instructions for use.

Source context: Feifel et al. — JAMA, October 26, 2026 · UK HRA — BPL-003-201 study and sponsor-supplied results summary

Read the safety information separately from the benefit

The sponsor's results summary hosted by the UK Health Research Authority reports two serious events in the initial study—depression in the low-dose group and agitation in the medium-dose group—judged unlikely to be related to the drug. It also reports a serious event considered related to BPL-003 in the subsequent open-label extension, which resolved.

This is a sponsor-supplied summary, not independent endorsement by the HRA. The accessible summary does not provide a complete event-level extension analysis; we do not turn it into an unsupported numerical safety comparison. Follow-up, adverse-event monitoring and psychiatric screening remain central research questions.

Source context: UK HRA — BPL-003-201 study and sponsor-supplied results summary

Keep established care in the conversation

NIMH describes psychotherapy, medication and, for some people whose depression persists, brain-stimulation treatments and specialist options. Treatment selection depends on the person's assessment, history and preferences. Research participation has a different purpose: it tests unresolved questions rather than promising benefit.

Ask a clinician to review what has actually been tried, how benefit and side effects were assessed, and what options remain. Do not stop medication to copy a study's enrollment procedures. Any change needs the treating clinician's guidance.

Source context: NIMH — Depression: treatment and support

A useful appointment conversation

Bring a brief treatment history instead of a demand for a particular new product. The following are planning prompts, not a checklist that determines medical eligibility.

What might explain the limited benefit from previous treatment?
Which established options fit my diagnosis and priorities now?
How would any clinical trial differ from ordinary care, including visits, costs, risks and follow-up?
Who is responsible if symptoms worsen during or after research participation?
What would count as meaningful improvement in daily life—not just a score?
How will the team check for bipolar symptoms, psychosis, substance-related risks and other factors that affect safety?

Support a person, not a treatment headline

A helpful response can be: ‘Would you like help writing down questions or getting to your appointment?’ Avoid implying that someone must keep chasing the newest intervention to deserve support. Respect their choices about what to share and who participates in care.

For a suicide or emotional crisis in the United States, call or text 988. Call 911 for immediate danger. Research updates and planning resources are not emergency care.